Evaluation of surrogate tissues as indicators of drug activity in a melanoma skin model
Authors:
Open Access
- 23 June 2016
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 5 (8) , 1731-1741
Abstract
The development of novel cancer treatments is a challenging task, partly because results from model systems often fail to predict drug efficacy in humans, and also tumors are often inaccessible for biochemical analysis, preventing effective monitoring of drug activity in vivo. Utilizing a model system, we evaluated the use of drug-induced DNA damage in surrogate tissues as indicators of drug efficacy. Samples of a commercially available melanoma skin model (Mattek MLNM-FT-A375) containing keratinocyte and fibroblast layers with melanoma nodules were subjected to various chemotherapeutic regimens for one, four, or eight days. At these times they were analyzed for DNA double-stranded breaks (γH2AX foci) and apoptosis (TUNEL). A wide range of drug responses in both tumor and normal tissues were observed and cataloged. For the melanoma, the most common drug response was apoptosis. The basal keratinocyte layer, which was the most reliable indicator of drug response in the melanoma skin model, responded with γH2AX foci formation that was abrupt and transient. The relationships between tumor and surrogate tissue drug responses are complex, indicating that while surrogate tissue drug responses may be useful clinical tools, careful control of variables such as the timing of sampling may be important in interpreting the results.Keywords
Funding Information
- National Cancer Institute
- National Institutes of Health
This publication has 42 references indexed in Scilit:
- Randomized Trial of the Combination of Lomeguatrib and Temozolomide Compared With Temozolomide Alone in Chemotherapy Naive Patients With Metastatic Cutaneous MelanomaJournal of Clinical Oncology, 2007
- Melanocyte Expression of Survivin Promotes Development and Metastasis of UV-Induced Melanoma in HGF-Transgenic MiceCancer Research, 2007
- Temozolomide for the Treatment of Metastatic MelanomaCurrent Oncology, 2007
- Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)Blood, 2006
- Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastasesMolecular Cancer Therapeutics, 2006
- Histone deacetylase inhibitor FK228 suppresses the Ras–MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanomaOncogene, 2005
- Selective CD4+ Lymphopenia in Melanoma Patients Treated With Temozolomide: A Toxicity With Therapeutic ImplicationsJournal of Clinical Oncology, 2004
- MG‐63 human osteosarcoma cells grown in monolayer and as three‐dimensional tumor spheroids present a different metabolic profile: a 1H NMR studyFEBS Letters, 2003
- Apoptosis and efficient repair of DNA damage protect human keratinocytes against UVBCell Death & Differentiation, 2003
- Megabase Chromatin Domains Involved in DNA Double-Strand Breaks in VivoJournal of Cell Biology, 1999